PMID- 33052879 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230202 IS - 1945-4589 (Electronic) IS - 1945-4589 (Linking) VI - 12 IP - 19 DP - 2020 Oct 14 TI - Apremilast ameliorates ox-LDL-induced endothelial dysfunction mediated by KLF6. PG - 19012-19021 LID - 10.18632/aging.103665 [doi] AB - Apremilast is a phosphodiesterase 4 (PDE4) inhibitor used in the treatment of psoriasis and several other inflammatory diseases. Interest has been expressed in seeking out therapies that address both psoriasis and atherosclerosis. In the present study, we explored the effects of apremilast in human aortic endothelial cells (HAECs) exposed to oxidized low-density lipoprotein (ox-LDL) to simulate the atherosclerotic microenvironment in vitro. Our findings indicate that apremilast may reduce the expression of lectin-like oxidized-low-density-lipoprotein receptor-1 (LOX-1), the main ox-LDL scavenging receptor. Apremilast also inhibited the expression of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-8 (IL-8), which are deeply involved in the chronic inflammatory response associated with atherosclerosis. Interestingly, we found that apremilast inhibited the attachment of U937 monocytes to HAECs by reducing the expression of the chemokine monocyte chemotactic protein 1 (MCP-1) and the cellular adhesion molecule vascular cell adhesion molecule-1 (VCAM-1). This effect was found to be mediated through the rescue of Kruppel like factor 6 (KLF6) expression, which was reduced in response to ox-LDL via increased phosphorylation of c-Jun N-terminal kinase (JNK). These findings suggest a potential role for apremilast in the treatment of atherosclerosis. FAU - Wang, Hao AU - Wang H AD - Department of Cardiology, The Second Medical Center, National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing 100853, China. FAU - Yang, Guang AU - Yang G AD - Department of Nephrology, The Second Medical Center, National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing 100853, China. FAU - Zhang, Qian AU - Zhang Q AD - Department of Endocrinology, The Seventh Medical Center, Chinese PLA General Hospital, Beijing 100700, China. FAU - Liang, Xiao AU - Liang X AD - Department of Cardiology, The Second Medical Center, National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing 100853, China. FAU - Liu, Yang AU - Liu Y AD - Department of Nephrology, The Second Medical Center, National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing 100853, China. FAU - Gao, Meng AU - Gao M AD - Department of Cardiology, The Second Medical Center, National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing 100853, China. FAU - Guo, Yutao AU - Guo Y AD - Department of Cardiology, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China. FAU - Chen, Li AU - Chen L AD - Department of General Practice, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China. LA - eng PT - Journal Article DEP - 20201014 PL - United States TA - Aging (Albany NY) JT - Aging JID - 101508617 SB - IM PMC - PMC7732304 OTO - NOTNLM OT - KLF6 OT - apremilast OT - atherosclerosis OT - endothelial dysfunction OT - ox-LDL COIS- CONFLICTS OF INTEREST: These authors declare no conflicts of interest. EDAT- 2020/10/15 06:00 MHDA- 2020/10/15 06:01 PMCR- 2020/10/15 CRDT- 2020/10/14 17:59 PHST- 2020/05/07 00:00 [received] PHST- 2020/06/22 00:00 [accepted] PHST- 2020/10/15 06:00 [pubmed] PHST- 2020/10/15 06:01 [medline] PHST- 2020/10/14 17:59 [entrez] PHST- 2020/10/15 00:00 [pmc-release] AID - 103665 [pii] AID - 10.18632/aging.103665 [doi] PST - ppublish SO - Aging (Albany NY). 2020 Oct 14;12(19):19012-19021. doi: 10.18632/aging.103665. Epub 2020 Oct 14.